Ionis reports positive Phase 3 olezarsen results; 100% reduction in pancreatitis in FCS

IONIS PHARMACEUTICALS INC

Olezarsen 80 mg achieved primary endpoint with significant triglyceride reduction vs placebo (p=0.0009) at six months.
Acute pancreatitis events reduced 100% (0 events for olezarsen vs 11 for placebo) over 12 months.
Favorable safety profile; no hepatic/renal toxicity, no clinically meaningful platelet reductions.
Ionis plans to file NDA with FDA early 2024; potential first approved treatment for FCS in US.
Phase 3 studies continuing in broader severe hypertriglyceridemia (SHTG) population.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.